Ask Warren

Biotoxtech

086040 · KOSDAQ · ₩086040 · 바이오톡스텍

₩2,110▲ ₩30 (1.44%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩14B₩12B₩14B₩12B₩9.6B₩11B₩11B₩11B
Cost of sales₩12B₩11B₩11B₩11B₩9B₩10B₩10B₩10B
Gross profit₩2.5B₩999M₩2.7B₩1.3B₩640M₩1.2B₩1.3B₩973M
Operating income−₩182M−₩1.8B−₩98M−₩1.4B−₩1.9B−₩1.4B−₩1.4B−₩2B
Net income−₩4.2B−₩2.7B−₩6B₩6.5B₩57M−₩2.1B−₩9.8B₩366M
Net income to shareholders−₩5.8B−₩1.9B−₩1.8B₩5.5B−₩1B−₩1.5B−₩2.1B−₩1.2B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩132B₩130B₩132B₩132B₩131B₩134B₩136B₩147B
Current assets₩53B₩46B₩49B₩52B₩52B₩56B₩59B₩64B
Cash and equivalents₩15B₩16B₩19B₩14B₩15B₩17B₩11B₩11B
Total liabilities₩110B₩101B₩100B₩98B₩100B₩101B₩102B₩108B
Current liabilities₩97B₩87B₩85B₩83B₩83B₩83B₩82B₩87B
Borrowings₩41B₩36B₩38B₩39B₩41B₩42B₩42B₩42B
Total equity₩22B₩29B₩32B₩34B₩31B₩33B₩35B₩39B
Shareholders' equity₩33B₩38B₩40B₩42B₩38B₩39B₩40B₩46B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩450M₩604M₩5.7B−₩355M₩649M₩600M₩3.8B−₩8.7B
Capital spending₩646M₩1.6B₩224M₩1.2B₩79M₩645M₩207M₩934M
Free cash flow−₩1.1B−₩993M₩5.5B−₩1.5B₩570M−₩44M₩3.6B−₩9.6B

Consolidated where available. Amounts in won.

Also known as: Biotoxtech / 바이오톡스텍 / 086040 / KRX:086040

Source: KRX statistical information